Harvard Bioscience (HBIO) Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 15.75% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 15.75% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 5.89% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.2 million, up from $1.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for HBIO reached as high as $4.8 million in Q1 2022 and fell as low as $1.7 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $3.1 million in 2022.
• Across the five-year window, Accumulated Expenses jumped 77.57% in 2022 and slumped 56.38% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $3.5 million in 2022, then advanced by 13.03% to $3.9 million in 2023, then slumped by 56.38% to $1.7 million in 2024, then grew by 5.89% to $1.8 million in 2025, then rose by 19.83% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.2 million in Q1 2026, $1.8 million in Q4 2025, and $1.9 million in Q3 2025.